Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety

Cladribine (CLAD) is a purine nucleoside analog approved in tablet form to treat highly active multiple sclerosis (MS). CLAD tablets are the first oral therapy with an infrequent dosing schedule, administered in two annual treatment courses, each divided into two treatment cycles comprising 4–5 days...

Descripción completa

Detalles Bibliográficos
Autores principales: Moser, Tobias, Ziemssen, Tjalf, Sellner, Johann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2022
Materias:
Main Topic
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026047/
https://www.ncbi.nlm.nih.gov/pubmed/35451662
http://dx.doi.org/10.1007/s10354-022-00931-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026047/
https://www.ncbi.nlm.nih.gov/pubmed/35451662
http://dx.doi.org/10.1007/s10354-022-00931-4

Ejemplares similares